Table 2

Number of records (and risk per 10 000 individuals) for acute and post-acute COVID-19 cardiac and thromboembolic complications, across cohorts and databases for any COVID-19 vaccination

CohortTime windowOutcomeCPRD AurumCORIVACPRD GoldSIDIAP
UnvaccinatedVaccinatedUnvaccinatedVaccinatedUnvaccinatedVaccinatedUnvaccinatedVaccinated
Cohort 1 n=346 674n=552 602n=23 982n=26 736n=169 100n=118 507n=223 962n=89 941
0 to 30 days VTE 93 (2.68)117 (2.12)77 (32.11)45 (16.83)8 (0.47)8 (0.68)74 (3.30)96 (10.67)
ATE 22 (0.63)70 (1.27)110 (45.87)81 (30.30)6 (0.35)7 (0.59)77 (3.44)208 (23.13)
HF 59 (1.70)198 (3.58)395 (164.71)299 (111.83)10 (0.59)9 (0.76)302 (13.48)640 (71.16)
31 to 90 days VTE 19 (0.55)40 (0.72)37 (15.43)30 (11.22)< 5< 516 (0.71)46 (5.11)
ATE 5 (0.14)43 (0.78)33 (13.76)47 (17.58)< 5< 541 (1.83)130 (14.45)
HF 30 (0.87)113 (2.04)151 (62.96)170 (63.58)< 58 (0.68)89 (3.97)298 (33.13)
91 to 180 days VTE 10 (0.29)21 (0.38)21 (8.76)35 (13.09)< 5< 520 (0.89)40 (4.45)
ATE 11 (0.32)28 (0.51)31 (12.93)52 (19.45)< 56 (0.51)30 (1.34)112 (12.45)
HF 37 (1.07)95 (1.72)162 (67.55)220 (82.29)< 55 (0.42)87 (3.88)252 (28.02)
181 to 365 days VTE 10 (0.29)11 (0.20)45 (18.76)35 (13.09)< 5< 510 (0.45)13 (1.45)
ATE 10 (0.29)23 (0.42)55 (22.93)82 (30.67)< 5< 542 (1.88)53 (5.89)
HF 40 (1.15)58 (1.05)268 (111.75)321 (120.06)< 56 (0.51)86 (3.84)149 (16.57)
Cohort 2 n=1 975 726 n=1 563 569n=34 317n=4572n=5 83 399n=4 86 619n=4 33 151n=8 19 590
0 to 30 days VTE 241 (1.22)220 (1.41)79 (23.02)7 (15.31)31 (0.53)24 (0.49)258 (5.96)400 (4.88)
ATE 41 (0.21)104 (0.67)110 (32.05)5 (10.94)< 56 (0.12)173 (3.99)669 (8.16)
HF 45 (0.23)146 (0.93)364 (106.07)23 (50.31)5 (0.09)13 (0.27)378 (8.73)1331 (16.24)
31 to 90 days VTE 43 (0.22)76 (0.49)31 (9.03)5 (10.94)< 59 (0.18)59 (1.36)195 (2.38)
ATE 18 (0.09)93 (0.59)32 (9.32)< 5< 59 (0.18)85 (1.96)444 (5.42)
HF 27 (0.14)103 (0.66)149 (43.42)19 (41.56)< 57 (0.14)138 (3.19)643 (7.85)
91 to 180 days VTE 28 (0.14)40 (0.26)26 (7.58)6 (13.12)6 (0.10)< 558 (1.34)125 (1.53)
ATE 17 (0.09)43 (0.28)32 (9.32)< 5< 5< 591 (2.10)417 (5.09)
HF 22 (0.11)69 (0.44)166 (48.37)21 (45.93)< 5< 5110 (2.54)579 (7.06)
181 to 365 days VTE 9 (0.05)13 (0.08)44 (12.82)8 (17.50)< 5< 516 (0.37)64 (0.78)
ATE 12 (0.06)18 (0.12)53 (15.44)< 5< 5< 563 (1.45)178 (2.17)
HF 20 (0.10)35 (0.22)259 (75.47)33 (72.18)< 5< 581 (1.87)246 (3.00)
Cohort 3 n=1 510 401n=1 528 031n=96 423n=24 050n=4 17 996n=4 62 832n=8 69 497n=9 54 232
0 to 30 days VTE 245 (1.62)142 (0.93)115 (11.93)9 (3.74)27 (0.65)17 (0.37)325 (3.74)180 (1.89)
ATE 29 (0.19)49 (0.32)119 (12.34)12 (4.99)< 512 (0.26)213 (2.45)275 (2.88)
HF 31 (0.21)38 (0.25)380 (39.41)23 (9.56)< 5< 5364 (4.19)256 (2.68)
31 to 90 days VTE 44 (0.29)46 (0.30)50 (5.19)10 (4.16)< 57 (0.15)85 (0.98)92 (0.96)
ATE 11 (0.07)33 (0.22)48 (4.98)9 (3.74)< 58 (0.17)109 (1.25)210 (2.20)
HF 15 (0.10)26 (0.17)180 (18.67)25 (10.40)< 5< 5137 (1.58)157 (1.65)
91 to 180 days VTE 24 (0.16)26 (0.17)43 (4.46)11 (4.57)< 5< 564 (0.74)101 (1.06)
ATE < 528 (0.18)44 (4.56)10 (4.16)< 5< 5113 (1.30)206 (2.16)
HF 11 (0.07)14 (0.09)216 (22.40)30 (12.47)< 5< 5120 (1.38)138 (1.45)
181 to 365 days VTE < 511 (0.07)72 (7.47)17 (7.07)< 5< 534 (0.39)26 (0.27)
ATE < 5< 580 (8.30)8 (3.33)< 5< 551 (0.59)67 (0.70)
HF 5 (0.03)< 5324 (33.60)37 (15.38)< 5< 562 (0.71)44 (0.46)
Cohort 4 n=2 027 763n=2 085 598n=1 47 545n=22 245n=4 69 876n=5 50 437n=1 061 634n=8 80 950
0 to 30 days VTE 334 (1.65)50 (0.24)116 (7.86)< 536 (0.77)11 (0.20)350 (3.30)98 (1.11)
ATE 26 (0.13)8 (0.04)116 (7.86)10 (4.50)< 5< 5231 (2.18)95 (1.08)
HF 28 (0.14)< 5364 (24.67)17 (7.64)< 5< 5362 (3.41)75 (0.85)
31 to 90 days VTE 58 (0.29)22 (0.11)54 (3.66)< 55 (0.11)< 591 (0.86)49 (0.56)
ATE 12 (0.06)9 (0.04)46 (3.12)5 (2.25)< 5< 5118 (1.11)76 (0.86)
HF 14 (0.07)9 (0.04)176 (11.93)13 (5.84)< 5< 5142 (1.34)47 (0.53)
91 to 180 days VTE 26 (0.13)10 (0.05)49 (3.32)5 (2.25)< 5< 571 (0.67)60 (0.68)
ATE < 56 (0.03)41 (2.78)7 (3.15)< 5< 5128 (1.21)90 (1.02)
HF 10 (0.05)< 5208 (14.10)18 (8.09)< 5< 5139 (1.31)55 (0.62)
181 to 365 days VTE < 5< 577 (5.22)< 5< 5< 546 (0.43)12 (0.14)
ATE < 5< 573 (4.95)9 (4.05)< 5< 554 (0.51)28 (0.32)
HF < 5< 5301 (20.40)16 (7.19)< 5< 557 (0.54)15 (0.17)
  • The four cohorts represent vaccine rollout periods.

  • ATE, arterial thrombosis/thromboembolism (Ischaemic stroke+transient ischaemic attack+myocardial infarction); HF, heart failure; VTE, venous thromboembolism (deep vein thrombosis+pulmonary embolism).